Modification of hepatitis b core antigen
CA 2413546 C · Owner: Pumpens, Paul · Inventors: Li, Jing-Li; Pumpens, Paul; Page, Mark
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A protein is provided comprising hepatitis B core antigen (HBcAg) wherein one or more of the four arginine repeats has been deleted said protein comprising , the C-terminal cysteine of HBcAg. The deleted region may be replaced by an epitope from a protein other than HBcAg in which case the HBcAg acts as a , carrier to present the epitope to the immune system. The chimeric protein is useful in prophylactic and therapeutic vaccination of a host for example , against hepatitis B virus.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 22, 2001 and granted June 14, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 22, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 22, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.